Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Zhong J, Zhang"'
Autor:
Maher Albitar, Francis Giles, Michael Keating, Jorge Cortes, Zeev Estrov, Elihu Estey, Susan O'Brien, Zhong J. Zhang, Xi Zhang, Amber C. Donahue, Benjamin Bekele, Hagop Kantarjian, Wanlong Ma
Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07f9a71c46b0fc1335d27e5216c074be
https://doi.org/10.1158/1078-0432.c.6517486.v1
https://doi.org/10.1158/1078-0432.c.6517486.v1
Publikováno v:
ChemElectroChem. 6:885-891
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ab8356c9f9c57c75e46323c7b3ab470
https://doi.org/10.1002/celc.201801855
https://doi.org/10.1002/celc.201801855
Autor:
Eunhee S. Yi, Daniel T. Merrick, Lauren M. Moore, Hadi Yaziji, Richard W. Cartun, Lynette M. Sholl, Patricia Gaule, Allen M. Gown, Jason L. Hornick, John J. McGuire, Balazs Acs, Jingxin Qiu, Zhong J. Zhang, David L. Rimm, Mary Beth Beasley, Jill Walker, Wei-Lien Wang, Delphine Cougot, Abiy B. Ambaye, Sandra Martinez-Morilla, Mari Mino-Kenudson
Publikováno v:
Laboratory investigation; a journal of technical methods and pathology
Programmed death 1 ligand 1 (PD-L1) Immunohistochemistry (IHC) is the key FDA-approved predictive marker to identify responders to anti-PD1 axis drugs. Multiple PD-L1 IHC assays with various antibodies and cut points have been used in clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1e5cf2c83be1eafb11019058c4ef3a
https://pubmed.ncbi.nlm.nih.gov/31409885
https://pubmed.ncbi.nlm.nih.gov/31409885
Autor:
Kevin Qu, Sugganth Daniel, Mohammad Reza Sheikholeslami, Suzzette Arnal, Sirisha Sunkara, Charles Ma, Zhong J. Zhang, Felicitas Lacbawan
Publikováno v:
Cancer Research. 79:4026-4026
Background: MSI status, along with PD-L1 expression and tumor mutational burden (TMB), is an important predictive biomarker for immune checkpoint inhibitors. Recent studies demonstrated that next-generation sequencing (NGS)-based MSI assays can simul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b403a35d62e2bbe39aebe8675242bf11
https://doi.org/10.1158/1538-7445.am2019-4026
https://doi.org/10.1158/1538-7445.am2019-4026
Autor:
Janese Trimaldi, Ling Zhang, Steven J. Agosti, Loveleen Kang, Alan F. List, Estrella M. Carballido, Bijal D. Shah, Jeremy W. Bowers, Zhong J. Zhang, Salvador Bruno, Terrence Grady, Lynn C. Moscinski, Arturo Anguiano
Publikováno v:
Acta Haematologica. 130:127-134
Myeloid and lymphoid neoplasms with fibroblastic growth factor receptor-1 (FGFR1) abnormalities originate from mutated pluripotent stem cells and have a heterogeneous clinical presentation. There are 12 identified partner genes commonly involved in F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc2eb1f365972377800642ee5d6ef5d6
https://doi.org/10.1159/000347030
https://doi.org/10.1159/000347030
Autor:
Wanlong Ma, Zhong J. Zhang, Xi Zhang, M. Albitar, Francis J. Giles, Xiuqiang Wang, Tai-Sung Lee, Chen-Hsiung Yeh
Publikováno v:
International Journal of Laboratory Hematology. 33:326-331
Summary Introduction: Multiple types of mutations in the BCR-ABL1 kinase domain have been reported. We previously reported a common alternatively spliced BCR-ABL mRNA with a 35-nucleotide insertion (35INS). We report three novel alternative splicing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c008633cc041f73644cdccce2333047
https://doi.org/10.1111/j.1751-553x.2010.01291.x
https://doi.org/10.1111/j.1751-553x.2010.01291.x
Autor:
Elihu H. Estey, Wanlong Ma, Benjamin N. Bekele, Hagop M. Kantarjian, Zhong J. Zhang, Maher Albitar, Jorge E. Cortes, Amber C. Donahue, Zeev Estrov, Francis J. Giles, Susan O'Brien, Xi Zhang, Michael J. Keating
Publikováno v:
Clinical Cancer Research. 15:3820-3826
Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bece936783acf72120d1ac65567c5eaa
https://doi.org/10.1158/1078-0432.ccr-08-3034
https://doi.org/10.1158/1078-0432.ccr-08-3034
Autor:
Benjamin N. Bekele, A. Ferrajoli, William G. Wierda, Iman Jilani, Chongjuan Wei, Zeev Estrov, M. Albitar, Susan O'Brien, Zhong J. Zhang, Hagop M. Kantarjian, Francis J. Giles, M. Keating
Publikováno v:
International Journal of Laboratory Hematology. 31:97-105
Syndecan-1 (sCD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed in epithelial cells as well as hematopoietic cells that demonstrate plasmacytoid differentiation. Higher levels of sCD138 correlate with poor outcome in myeloma. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c49683b967b8da2f412f667f389e40b2
https://doi.org/10.1111/j.1751-553x.2007.01010.x
https://doi.org/10.1111/j.1751-553x.2007.01010.x
Autor:
Y Kuramitsu, Y Sakawa, T Morita, T Ide, K Nishio, H Tanji, H Aoki, S Dono, C D Gregory, J N Waugh, N Woolsey, A Diziere, A Pelka, A Ravasio, B Loupias, M Koenig, S A Pikuz, Y T Li, Y Zhang, X Liu, J Y Zhong, J Zhang, G Gregori, N Nakanii, K Kondo, Y Mori, E Miura, R Kodama, Y Kitagawa, K Mima, K A Tanaka, H Azechi, T Moritaka, Y Matsumoto, T Sano, A Mizuta, N Ohnishi, M Hoshino, H Takabe
Publikováno v:
Plasma physics and controlled fusiom.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=erc_________::67bd5b796d75a2b0530a3772c09d174f
Autor:
Heather R. Sanders, Debra Boles, Zhong J Zhang, Christine R. Bryke, Philip N. Mowrey, Steven Schonberg, Albert K Ho, Dan Jones, Jennifer A. Otani-Rosa, Aurelia Meloni-Ehrig, Zunyan Dai, Nicole C. Christacos, Marilyn L. Slovak, JoAnn C. Kelly, Qiulu Pan
Publikováno v:
Molecular Cytogenetics
Molecular Cytogenetics, Vol 5, Iss 1, p 44 (2012)
Molecular Cytogenetics, Vol 5, Iss 1, p 44 (2012)
Background Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements have been reported in 2-13% of patients with non-small cell lung cancer (NSCLC). Patients with ALK rearrangements do not respond to EGFR-specific tyrosine kinase inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f606bf1cda87598672ce3cc4fab31666
https://pubmed.ncbi.nlm.nih.gov/23198868
https://pubmed.ncbi.nlm.nih.gov/23198868